Morgan Stanley Oncolytics Biotech Inc Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Oncolytics Biotech Inc stock. As of the latest transaction made, Morgan Stanley holds 17,353 shares of ONCY stock, worth $20,997. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,353

Previous 22,853 24.07%

Holding current value

$20,997

Previous $21,000 57.14%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.55 - $0.93 $3,025 - $5,115	-5,500 Reduced 24.07%	17,353 $9,000
Q4 2024 Feb 14, 2025	SELL	$0.74 - $1.4 $2,729 - $5,164	-3,689 Reduced 13.9%	22,853 $21,000
Q3 2024 May 14, 2025	SELL	$0.87 - $1.08 $97,421 - $120,937	-111,979 Reduced 80.84%	26,542 $23,000
Q3 2024 Nov 14, 2024	SELL	$0.87 - $1.08 $97,421 - $120,937	-111,979 Reduced 80.84%	26,542 $23,000
Q2 2024 May 14, 2025	BUY	$0.99 - $1.24 $114,511 - $143,428	115,668 Added 506.14%	138,521 $137,000
Q2 2024 Oct 17, 2024	SELL	$0.99 - $1.24 $207,694 - $260,142	-209,792 Reduced 60.23%	138,521 $137,000
Q2 2024 Aug 14, 2024	SELL	$0.99 - $1.24 $207,694 - $260,142	-209,792 Reduced 60.23%	138,521 $137,000
Q1 2024 Oct 17, 2024	BUY	$0.89 - $1.36 $186,714 - $285,317	209,792 Added 151.45%	348,313 $369,000
Q1 2024 Aug 16, 2024	BUY	$0.89 - $1.36 $104,065 - $159,022	116,928 Added 50.53%	348,313 $369,000
Q1 2024 May 15, 2024	BUY	$0.89 - $1.36 $104,065 - $159,022	116,928 Added 50.53%	348,313 $369,000
Q4 2023 Aug 16, 2024	BUY	$1.22 - $2.09 $113,294 - $194,085	92,864 Added 67.04%	231,385 $312,000
Q4 2023 Feb 13, 2024	BUY	$1.22 - $2.09 $206,047 - $352,982	168,891 Added 270.25%	231,385 $312,000
Q3 2023 Nov 15, 2023	SELL	$1.98 - $3.24 $241,003 - $394,369	-121,719 Reduced 66.08%	62,494 $136,000
Q2 2023 Aug 14, 2023	BUY	$1.11 - $2.74 $85,723 - $211,604	77,228 Added 72.19%	184,213 $478,000
Q1 2023 May 15, 2023	BUY	$1.2 - $1.91 $3,330 - $5,300	2,775 Added 2.66%	106,985 $128,000
Q4 2022 Feb 14, 2023	BUY	$1.17 - $2.12 $6,706 - $12,151	5,732 Added 5.82%	104,210 $169,000
Q3 2022 Nov 14, 2022	BUY	$0.98 - $1.51 $6,455 - $9,946	6,587 Added 7.17%	98,478 $121,000
Q2 2022 Oct 27, 2022	BUY	$0.85 - $1.59 $27,647 - $51,716	32,526 Added 54.79%	91,891 $93,000
Q2 2022 Aug 15, 2022	BUY	$0.85 - $1.59 $27,647 - $51,716	32,526 Added 54.79%	91,891 $93,000
Q1 2022 Oct 27, 2022	SELL	$1.31 - $2.02 $42,609 - $65,702	-32,526 Reduced 35.4%	59,365 $94,000
Q1 2022 May 13, 2022	SELL	$1.31 - $2.02 $36,922 - $56,933	-28,185 Reduced 32.19%	59,365 $94,000
Q4 2021 Feb 14, 2022	BUY	$1.39 - $2.3 $6,113 - $10,115	4,398 Added 5.29%	87,550 $122,000
Q3 2021 Nov 15, 2021	BUY	$1.93 - $2.77 $160,483 - $230,331	83,152 New	83,152 $174,000

Others Institutions Holding ONCY

# of Institutions

Shares Held

1.37M

Call Options Held

Put Options Held

View Full List

About ONCOLYTICS BIOTECH INC

Ticker ONCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,867,400
Market Cap $70M
Description
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...

More about ONCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account